SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Dec. 16, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Skye Bioscience, Inc. (“Skye” or “the Company”) (
NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Bragar Eagel & Squire, P.C. Urges DeFi, Skye Bioscience, and Perrigo Investors to Contact the Firm Regarding their RightsNEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of DeFi Technologies Inc. (
NASDAQ: DEFT), Skye Bioscience, Inc. (
NASDAQ:SKYE) and Perrigo Company plc (
NYSE:PRGO). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Berger Montague PC Investigating Claims on Behalf of Skye Bioscience, Inc. (NASDAQ: SKYE) Investors After Class Action FilingPHILADELPHIA, Dec. 15, 2025 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (
NASDAQ: SKYE) (“Skye” or the “Company”) on behalf of investors who purchased or otherwise acquired Skye securities during the period of November 4, 2024 through October 3, 2025 (the “Class Period”), inclusive.
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Skye Bioscience, Inc. (“Skye” or “the Company”) (
NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Skye Bioscience, Inc. (“Skye” or “the Company”) (
NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Dec. 05, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Skye Bioscience, Inc. (“Skye” or “the Company”) (
NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Bragar Eagel & Squire, P.C. Urges DeFi, Skye Bioscience, and Perrigo Investors to Contact the Firm Regarding their RightsNEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of DeFi Technologies Inc. (
NASDAQ: DEFT), Skye Bioscience, Inc. (
NASDAQ:SKYE) and Perrigo Company plc (
NYSE:PRGO). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
SKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye BioscienceFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Skye Bioscience, Inc. (“Skye” or “the Company”) (
NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye BioscienceFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Skye Bioscience and Perrigo and Encourages Investors to Contact the FirmNEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Skye Bioscience, Inc. (
NASDAQ:SKYE) and Perrigo Company plc (
NYSE:PRGO). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Nov. 28, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Skye Bioscience, Inc. (“Skye” or “the Company”) (
NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SKYE
The DJS Law Group reminds investors of a class action lawsuit against Skye Bioscience, Inc. (“Skye” or “the Company”) (
NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Nov. 25, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Skye Bioscience, Inc. (“Skye” or “the Company”) (
NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Bragar Eagel & Squire, P.C. Reminds Stockholders Spirit, Molina, Skye, and Perrigo of the Upcoming Deadlines and Urges Investors to Contact the FirmNEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Spirit Aviation Holdings, Inc. (OTCMKTS:FLYYQ), Molina Healthcare, Inc. (
NYSE: MOH), Skye Bioscience, Inc. (
NASDAQ:SKYE), and Perrigo Company plc (
NYSE:PRGO). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Lost Money on Skye Bioscience, Inc. (SKYE)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskySearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Lost Money on Skye Bioscience, Inc. (SKYE)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskyNEW YORK - November 24, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Skye Bioscience, Inc. (
NASDAQ: SKYE) of a class action securities lawsuit.
Skye Bioscience to Participate in Upcoming Investment ConferencesSan Diego, California--(Newsfile Corp. - November 24, 2025) - Skye Bioscience, Inc. (
NASDAQ: SKYE) ("Skye"), a clinical-stage biotechnology company focused...
